Skip to content Skip to footer
Close
team-molteni

Dr.

Dr. Franco Molteni

Dr Franco Molteni is the director of Valduce Rehabilitation Hospital in Como, Italy. He obtained his medical degree in Milan University, Italy in 1981 and his board certification in 1984 in PM&R in the same university

Italy

Biography

Dr Franco Molteni obtained his medical degree in Milan University, Italy in 1981 and his board certification in 1984 in PM&R in the same university. In 1999 he undertook an international collaboration with the Moss Rehabilitation Center in Philadelphia, USA.

Since 2004 , he has been Clinical Director of the Valduce Rehabilitation Hospital in Como, Italy where he has also worked extensively in the hospital’s research program.

He is Member of the Italian Society of Physical Medicine and Rehabilitation, the Valduce Foundation and Honorary Member of the Royal Belgian Society of Physical Medicine and Rehabilitation. His Scientific Collaborations include: Movendo Technology Italy; Merz Pharmaceuticals GmbH Germany; IUVO Italy; University of Padova Italy; University of Torino Italy; University of Milan Italy; Politecnico of Milan Italy.

Other team members

team-balbert

Dr. Alexander Balbert

team-baricich

Prof. Alessio Baricich

team-bensmail

Prof. Djamel Bensmail

team-Bianchi

Dr.ssa. Francesca Bianchi

team-biering-sorenson

Dr. Bo Biering-Sørensen

team-carda

Dr. Stefano Carda

team-deltombe2

Prof. Thierry Deltombe

team-draulans

Dr. Nathalie Draulans

team-escaldi

Dr. Steven V. Escaldi

team-Francisco

Dr. Gerard E. Francisco

team-Gross

Prof. Raphaël Johannes Gross

team-JACINTO-teste

Dr. Luis Jorge Jacinto

team-odell

Prof. Michael O’Dell

team-Picelli

Prof. Alessandro Picelli

team-reebye

Prof. Rajiv Reebye

team-Santamato

Prof. Andrea Santamato

team-verduzco

Prof. Monica Verduzco-Gutierrez

team-walker

Dr. Heather Walker

team-wissel

Prof. Jörg Wissel

team-zimmerman

Dr. Maximo Zimerman

Brenda McCleary, an independent consultant, provides general management and scientific support for Toxnet projects.

© 2024 ToxNet. All Rights Reserved.

Supported by Merz Therapeutics GmbH

Liability for links
Our site contains links to external websites, over which we have no control. Therefore we cannot accept any responsibility for this external content. The respective provider or operator is always responsible for the contents of any linked site. At the time of linking the linked sites where checked for possible legal violations. At the time of linking illegal contents were not indicated. A permanent control of the linked pages is unreasonable without concrete evidence of violation. Upon notification of violations, we will remove such links immediately.

Award scoring criteria

The following criteria will be judged out of a score of 5; (1 is suboptimal; 2 is adequate; 3 is good; 4 is very good; 5 is excellent)

GENERAL

  • Days per week working in spasticity management
  • Average number of spasticity patients managed per month
  • Environment and clinical team (type of institution, location, size/structure of clinical team, particular patient needs)
  • Role of responsibility in managing patients with spasticity
  • Scientific appointments in spasticity
  • Honours for work undertaken in spasticity

SCHOLARLY

  • Number of research projects investigating relevant aspects of spasticity management
  • Impact of research projects investigating relevant aspects of spasticity management
  • Number of peer-reviewed publications on topic
    Number of presentations of research at international meetings
  • Number of presentations at national conferences
  • Teaching/mentorship of younger injectors
  • h-index

CLINICAL

  • Evidence of development or growth of a spasticity program at the applicant’s practice or institution
  • Breadth of services provided, including medications, toxins, physical interventions, and Intrathecal Baclofen Therapy (ITB)
  • Role of responsibility in managing patients with spasticity

ENDORSEMENT

  • Endorsed by senior peer

In the event of a tie, based on the above scoring criteria, the Toxnet Co-Chairs will make the final decision.